Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites

Biochemical Pharmacology

Volumn 84, Issue 2, 2012, Pages 215-223

  Ghassabian, Sussan ^a   Rawling, Tristan ^a   Zhou, Fanfan ^a   Doddareddy, Munikumar R ^a   Tattam, Bruce N ^a   Hibbs, David E ^a   Edwards, Robert J ^b   Cui, Pei H ^a   Murray, Michael ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

CYP3A4; Hepatoma; Sorafenib; Sorafenib biotransformation; Tyrosine kinase inhibitors

Indexed keywords

COMPLEMENTARY DNA; CYTOCHROME P450 3A4; DRUG METABOLITE; KETOCONAZOLE; METHYL GROUP; MIDAZOLAM; OXIDE; QUERCETIN; SORAFENIB; UNSPECIFIC MONOOXYGENASE;

ARTICLE; ATOM; CATALYST; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYDROXYLATION; DRUG OXIDATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROGEN BOND; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL;

BENZENESULFONATES; CATALYTIC DOMAIN; CYTOCHROME P-450 CYP3A; HUMANS; METABOLIC DETOXICATION, DRUG; MICROSOMES, LIVER; MODELS, MOLECULAR; OXIDATION-REDUCTION; PROTEIN CONFORMATION; PYRIDINES;

EID: 84861227075     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2012.04.001     Document Type: Article

References (48)

1. H.I. Yang, S.H. Yeh, P.J. Chen, U.H. Iloeje, C.L. Jen, and J. Su Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma J Natl Cancer Inst 100 16 2008 1134 1143
2. F. Stickel, and C. Hellerbrand Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications Gut 59 10 2010 1303 1307
3. V.W. Setiawan, D.O. Stram, A.M. Nomura, L.N. Kolonel, and B.E. Henderson Risk factors for renal cell cancer: the multiethnic cohort Am J Epidemiol 166 8 2007 932 940
4. L. Liu, Y. Cao, C. Chen, X. Zhang, A. McNabola, and D. Wilkie Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5 Cancer Res 66 24 2006 11851 11858
5. S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, and R.A. Smith Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 10 2006 835 844
6. M.J. Ratain, T. Eisen, W.M. Stadler, K.T. Flaherty, S.B. Kaye, and G.L. Rosner Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma J Clin Oncol 24 16 2006 2505 2512
7. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 4 2008 378 390
8. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Siebels Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2 2007 125 134
9. EMEA (European Medicines Agency). Nexavar: EPAR - summary for the public; 2009. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/000690/human-med-000929.jsp&murl=menus/medicines/ medicines.jsp&mid=WC0b01ac058001d125 [accessed 28/12/2011].
10. C. Lathia, J. Lettieri, F. Cihon, M. Gallentine, M. Radtke, and P. Sundaresan Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics Cancer Chemother Pharmacol 57 5 2006 685 692
11. D.A. Reardon, J.J. Vredenburgh, A. Desjardins, K. Peters, S. Gururangan, and J.H. Sampson Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma J Neurooncol 101 1 2011 57 66
12. M. Sugiyama, K. Fujita, N. Murayama, Y. Akiyama, H. Yamazaki, and Y. Sasaki Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1′-hydroxylation Drug Metab Dispos 39 5 2011 757 762
13. R.J. Edwards, D.A. Adams, P.S. Watts, D.S. Davies, and A.R. Boobis Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans Biochem Pharmacol 56 1998 377 387
14. D. Bankston, J. Dumas, R. Natero, B. Riedl, M-K. Monahan, and R. Sibley A scaleable synthesis of BAY 43-9006: a potent raf kinase inhibitor for the treatment of cancer Org Process Res Dev 6 2002 777 781
15. 14C]Nexavar™ and its labeled metabolites J Labelled Compd Radiopharm 49 2006 603 613
16. M. Murray, L. Zaluzny, and G.C. Farrell Impaired androgen 16α-hydroxylation in hepatic microsomes from carbon tetrachloride- cirrhotic male rats Gastroenterology 93 1 1987 141 147
17. O.H. Lowry, N.J. Rosebrough, A.L. Farr, and R.J. Randall Protein measurement with the folin phenol reagent J Biol Chem 193 1 1951 265 275
18. M. Zhao, M.A. Rudek, P. He, F.T. Hafner, M. Radtke, and J.J. Wright A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay J Chromatogr B Analyt Technol Biomed Life Sci 846 1-2 2007 1 7
19. R.A. Prough, M.D. Burke, and R.T. Mayer Direct fluorometric methods for measuring mixed function oxidase activity Methods Enzymol 52 1978 372 377
20. J.S. Miles, A.W. McLaren, L.M. Forrester, M.J. Glancey, M.A. Lang, and C.R. Wolf Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity Biochem J 267 2 1990 365 371
21. K.A. Mortier, V. Renard, A.G. Verstraete, A. Van Gussem, S. Van Belle, and W.E. Lambert Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of docetaxel and paclitaxel in human plasma and oral fluid Anal Chem 77 14 2005 4677 4683
22. R.G. Knodell, S.D. Hall, G.R. Wilkinson, and F.P. Guengerich Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition J Pharmacol Exp Ther 241 3 1987 1112 1119
23. W.V. Zhang, F. d'Esposito, R.J. Edwards, I. Ramzan, and M. Murray Inter-individual variation in relative CYP1A2/3A4 phenotype influences susceptibility of clozapine oxidation to CYP-specific inhibition in human hepatic microsomes Drug Metab Dispos 36 12 2008 2547 2555
24. M. Murray Microsomal cytochrome P450-dependent steroid metabolism in male sheep liver: quantitative importance of 6β-hydroxylation and evidence for the involvement of a P450 from the IIIA subfamily in the pathway J Steroid Biochem Mol Biol 38 5 1991 611 619
25. M. Murray In vitro and in vivo studies of the effect of vitamin E on microsomal cytochrome P450 in rat liver Biochem Pharmacol 42 11 1991 2107 2114
26. C. Knox, V. Law, T. Jewison, P. Liu, S. Ly, and A. Frolkis DrugBank 3.0: a comprehensive resource for 'omics' research on drugs Nucleic Acids Res 39 2011 D1035 D1041
27. R.A. Friesner, R.B. Murphy, M.P. Repasky, L.L. Frye, J.R. Greenwood, and T.A. Halgren Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes J Med Chem 49 21 2006 6177 6196
28. J.K. Yano, M.R. Wester, G.A. Schoch, K.J. Griffin, C.D. Stout, and E.F. Johnson The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05- resolution J Biol Chem 279 37 2004 38091 38094
29. I.F. Sevrioukova, and T.L. Poulos Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir Proc Natl Acad Sci USA 107 43 2010 18422 18427
30. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F.P. Guengerich Interindividual variation in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians J Pharmacol Exp Ther 270 1 1994 414 423
31. R. Wolbold, K. Klein, O. Burk, A.K. Nüssler, P. Neuhaus, and M. Eichelbaum Sex is a major determinant of CYP3A4 expression in human liver Hepatology 38 4 2003 978 988
32. E. Hustert, M. Haberl, O. Burk, R. Wolbold, Y.Q. He, and K. Klein The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 9 2001 773 779
33. P. Kuehl, J. Zhang, Y. Lin, J. Lamba, M. Assem, and J. Schuetz Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 4 2001 383 391
34. Y.S. Lin, A.L. Dowling, S.D. Quigley, F.M. Farin, J. Zhang, and J. Lamba Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism Mol Pharmacol 62 1 2002 162 172
35. W. Huang, Y.S. Lin, D.J. McConn 2nd, J.C. Calamia, R.A. Totah, and N. Isoherranen Evidence of significant contribution from CYP3A5 to hepatic drug metabolism Drug Metab Dispos 32 12 2004 1434 1445
36. J.S. Lind, A.M. Dingemans, H.J. Groen, F.B. Thunnissen, O. Bekers, and D.A. Heideman A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer Clin Cancer Res 16 11 2010 3078 3087
37. M. Ekroos, and T. Sjögren Structural basis for ligand promiscuity in cytochrome P450 3A4 Proc Natl Acad Sci USA 103 37 2006 13682 13687
38. G.R. Harlow, and J.R. Halpert Analysis of human cytochrome P450 3A4 cooperativity: construction and characterization of a site-directed mutant that displays hyperbolic steroid hydroxylation kinetics Proc Natl Acad Sci USA 95 12 1998 6636 6641
39. G.R. Harlow, and J.R. Halpert Alanine-scanning mutagenesis of a putative substrate recognition site in human cytochrome P450 3A4. Role of residues 210 and 211 in flavonoid activation and substrate specificity J Biol Chem 272 9 1997 5396 5402
40. M. Jayakanthan, S. Chandrasekar, J. Muthukumaran, and P.P. Mathur Analysis of CYP3A4-HIV-1 protease drugs interactions by computational methods for Highly Active Antiretroviral Therapy in HIV/AIDS J Mol Graph Model 28 5 2010 455 463
41. H. Akaza, T. Tsukamoto, M. Murai, K. Nakajima, and S. Naito Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma Jap J Clin Oncol 37 10 2007 755 762
42. D. Strumberg, J.W. Clark, A. Awada, M.J. Moore, H. Richly, and A. Hendlisz Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors Oncologist 12 4 2007 426 437
43. H. Minami, K. Kawada, H. Ebi, K. Kitagawa, Y.I. Kim, and K. Araki Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors Cancer Sci 99 7 2008 1492 1498
44. L.L. von Moltke, D.J. Greenblatt, S.X. Duan, J.S. Harmatz, and R.I. Shader In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction J Clin Pharmacol 34 12 1994 1222 1227
45. D.J. Greenblatt, K. Venkatakrishnan, J.S. Harmatz, S.J. Parent, and L.L. von Moltke Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro Xenobiotica 40 10 2010 713 720
46. 50: a more general use for the Dixon plot J Chem Educ 80 2 2003 214 218
47. N.R. Badcock, F.D. Bartholomeusz, D.B. Frewin, L.N. Sansom, and J.G. Reid The pharmacokinetics of ketoconazole after chronic administration in adults Eur J Clin Pharmacol 33 5 1987 531 534
48. R. Martínez-Jordá, J.M. Rodriguez-Sasiain, E. Suárez, and R. Calvo Serum binding of ketoconazole in health and disease Int J Clin Pharmacol Res 10 5 1990 271 276